Recombinant N-Cadherin antibody (full length)
Quick Overview for Recombinant N-Cadherin antibody (full length) (ABIN7877743)
Target
See all N-Cadherin (CDH2) AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
Clone
-
-
Binding Specificity
- full length
-
Purpose
- Recombinant N-Cadherin Antibody / CDH2 / CD325 (azide and preservative free)
-
Purification
- Protein G affinity chromatography
-
Immunogen
- Recombinant full-length human protein was used as the immunogen for the recombinant N-Cadherin antibody.
-
Isotype
- IgG1, kappa
-
-
-
-
Application Notes
- Optimal dilution of the recombinant N-Cadherin antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the recombinant N-Cadherin antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- N-Cadherin (CDH2) (Cadherin 2 (CDH2))
-
Alternative Name
- N-Cadherin
-
Background
- Recognizes a protein of ~140 kDa, identified as N-Cadherin (NCAD), also known as CD325 and CDH2. NCAD is a member of the Cadherin superfamily, and consists of five extracellular repeats, a transmembrane domain and a cytoplasmic domain. CD325 deficient mice die at day 10 of gestation and embryos display major heart defects and malformed neural tubes and somites. Consistent with this, CD325 has been implicated in several aspects of cardiac development including the precardiac mesoderm, establishment of left-right symmetry and cardiac looping morphogenesis. Furthermore, CD325 is normally involved in inducing cell cycle arrest and its expression is frequently deregulated in cancer cells.Studies have linked N-cadherin to cancer metastasis by showing the aggressive tumor cells had preferentially turned on N-cadherin as opposed to E- or P-cadherin.
-
UniProt
- P19022
-
Pathways
- Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Synaptic Membrane
Target
-